Women First to market Fournier's Esclim in US:
This article was originally published in Clinica
Women First HealthCare is to market the French company Groupe Fournier's FDA-approved oestradiol transdermal patch in the US. The Esclim patch is manufactured by Fournier's drug delivery subsidiary, Cross Site, based in Dijon, France. It is approved in 20 countries and is brand leader in France. The company claims it has the widest dosage options of any twice-weekly patch currently available in the US, where the transdermal patch market is estimated at $170 million. San Diego, California-based Women First develops and markets products aimed at menopausal women.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.